


Apelin-17(human, bovine)

Cat. No.:	HY-P1066
CAS No.:	217082-57-0
Molecular Formula:	C ₉₆ H ₁₅₆ N ₃₄ O ₂₀ S
Molecular Weight:	2138.55
Sequence:	Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe
Sequence Shortening:	KFRRQRPRLSHKGPMPPF
Target:	HIV
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture



Powder -80°C 2 years
-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (46.76 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.4676 mL	2.3380 mL	4.6761 mL
	5 mM		0.0935 mL	0.4676 mL	0.9352 mL
	10 mM		0.0468 mL	0.2338 mL	0.4676 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC₅₀=9.02). Apelin-17(human, bovine) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ^{[1][2][3]}.

IC₅₀ & Target

HIV-1

HIV-2

REFERENCES

[1]. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471-476.

[2]. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J

Neurochem. 2003;84(5):1162-1172.

[3]. Zou MX, et al. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett. 2000;473(1):15-18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA